NIH Awards iHealthScreen $2.7M in Funding!
We recently received $2.7M in funding from The National Institutes of Health! NIH is the largest public funder of biomedical research in the world.
Sharing the Same Mission
In fiscal year 2022, NIH invested most of its $45 billion appropriations in research. They invest in research that improves people's lives, focusing on reducing illness and disability.
NIH-funded research has led to breakthroughs and new treatments. Our team shares the same mission of helping people live longer. People deserve healthier lives, and we're achieving this by building a research foundation that drives discovery.
iHealthScreen is the first company in the world to receive CE certification to screen for three blinding eye diseases. (Glaucoma, Diabetic Retinopathy, Age-related macular degeneration).
We've developed a way to bring low-cost AI-driven screening software to primary care offices globally!
- Raised $750K as seed funding.
- Awarded $2.7M in NIH funding.
- Working on securing additional research grants.
- One US patent (the first patent in Late AMD prediction).
- One patent is pending, with four provisional patent applications submitted.
Thank You For Your Time!
Less than 1% of the market is taken by companies with FDA 510(K) clearance, making this a multi-billion-dollar market opportunity. This massive market is almost entirely untapped. Join us on StartEngine today!
Leave a Comment
iHealthScreen: Q&A Webinar Recap
Watch our webinar recap to learn about our unique opportunity to capitalize on AI-driven health screening software. CEO . […]
Glaucoma affects over 3 million people in the United States, and this number is projected to be 4.3 million by 2030 as t. […]
What is age-related macular degeneration?
age related macular degeneration (AMD) (Figure 1) is a retinal disorder and one of the leading causes of blindness in th. […]